Document is current
Any future updates will be listed below
-
Authors
Erwin, Graham S. https://orcid.org/0000-0002-9286-7626
Gürsoy, Gamze https://orcid.org/0000-0002-1352-8686
Al-Abri, Rashid https://orcid.org/0000-0002-5194-8454
Suriyaprakash, Ashwini https://orcid.org/0000-0003-1769-4814
Dolzhenko, Egor
Zhu, Kevin
Hoerner, Christian R.
White, Shannon M.
Ramirez, Lucia
Vadlakonda, Ananya
Vadlakonda, Alekhya
von Kraut, Konor
Park, Julia
Brannon, Charlotte M.
Sumano, Daniel A.
Kirtikar, Raushun A.
Erwin, Alicia A.
Metzner, Thomas J.
Yuen, Ryan K. C. https://orcid.org/0000-0001-7273-4968
Fan, Alice C.
Leppert, John T. https://orcid.org/0000-0001-9980-3863
Eberle, Michael A. https://orcid.org/0000-0001-8965-1253
Gerstein, Mark https://orcid.org/0000-0002-9746-3719
Snyder, Michael P. https://orcid.org/0000-0003-0784-7987
- License Information
-
More Information
Article History
Received: 13 August 2021
Accepted: 2 November 2022
First Online: 14 December 2022
Competing interests
: G.S.E. and M.P.S. are inventors on a patent application describing anti-proliferative agents. E.D. and M.A.E. are shareholders and are currently or were formerly employed by Illumina and Pacific Biosciences. The other authors declare no competing interests.
